Therapeutic Inhibitors against Mutated BRAF and MEK for the Treatment of Metastatic Melanoma
10.4068/cmj.2017.53.3.173
- Author:
Sunhyo RYU
1
;
Chakyung YOUN
;
Ae Ran MOON
;
Amanda HOWLAND
;
Cheryl A ARMSTRONG
;
Peter I SONG
Author Information
1. Department of Dermatology, University of Colorado Denver Medical School, Aurora, Colorado, USA. peter.song@ucdenver.edu
- Publication Type:Review
- Keywords:
Melanoma;
Vemurafenib;
Dabrafenib;
Sorafenib;
Mitogen-activated protein kinase kinases
- MeSH:
Biology;
Humans;
Immunotherapy;
Melanoma;
Mitogen-Activated Protein Kinase Kinases;
Phosphotransferases;
Skin Neoplasms
- From:Chonnam Medical Journal
2017;53(3):173-177
- CountryRepublic of Korea
- Language:English
-
Abstract:
Melanoma is one of the most aggressive cancers in the world and is responsible for the majority of skin cancer deaths. Recent advances in the field of immunotherapy using active, adoptive, and antigen-specific therapeutic approaches, have generated the expectation that these technologies have the potential to improve the treatment of advanced malignancies, including melanoma. Treatment options for metastatic melanoma patients have been dramatically improved by the FDA approval of new therapeutic agents including vemurafenib, dabrafenib, and sorafenib. These kinase inhibitors have the potential to work in tandem with MEK, PI3K/AKT, and mTOR to inhibit the activity of melanoma inducing BRAF mutations. This review summarizes the effects of the new therapeutic agents against melanoma and the underlying biology of these BRAF inhibitors.
